[1] Bonnet U. Moclobemide: therapeutic use and clinical studies [J]. CNS Drug Rev, 2003, 9 (1): 97-140. [2] Hu DD, Mao DZ, Pei YY. Preparation and thermodynamics of moclobemide-polyvinylpyrrolidone solid dispersion [J]. Fudan Univ J Med Sci, 2002, 29 (6): 492-494. [3] Dingemanse J, Wood N, Guentert T, et al. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects [ J]. Psychopharmacology, 1998, 140 (2): 164-172. [4] Fulton B, Benfield P. Moclobemide: an update of its pharmacological properties and therapeutic use [J]. Drugs, 1996, 52 (3): 450-474. [5] Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future [J]. Neurotoxicology, 2004, 25 (1): 215-221. [6] Amrein R, Martin JR, Cameron AM. Moclobemide in patients with dementia and depression [J]. Adv Neurol, 1999, 80 (5): 509-519. [7] Stein DJ, Cameron A, Amerin R, et al. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder [J]. Int Clin Psychopharmacol, 2002, 17 (4): 161-170. [8] Silverstone T. Moclobemide vs imipramine in bipolar depression: a multicentre double-blind clinical trial [J]. Acta Psychiatr Scand, 2001, 104 (2): 104-109. [9] Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide [J]. Clin Pharmacokinet, 1995, 29 (5): 292-332. [10] Bonnet U. Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties [J]. CNS Drug Rev, 2002, 8 (3): 283-308. [11] Misztal G, Skibinski R, Olajossy M, et al. LC determination of moclobemide and three metabolites in plasma [J]. J Pharm Biomed Anal, 2002, 30 (4): 1277-1285. [12] Hoskins JM, Gross AS, Shenfield GM, et al. High-performance liquid chromatography-electrospray ionization mass spectrometry method for the measurement of moclobemide and two metabolites in plasma [J]. J Chromatogr B, 2001, 754 (2): 319-326. |